AI specialists ink deal with Pfizer to target cardiac amyloidosis

Related Articles
Bridging ECG Signals and EHR data through Contrastive Learning
Introduction: How can we teach an AI to see the connections between a patient’s heart rhythms and their clinical notes? In healthcare, critical information is spread across different data types…January 22, 2026
Anumana earns first full FDA clearance for AI to detect low ejection fraction
Fierce Biotech: Two years after its launch as a joint venture between the Mayo Clinic and Nference to develop artificial intelligence algorithms capable of pulling out new insights from routine…October 05, 2023
FDA grants Breakthrough Device Designation to pulmonary hypertension early detection AI
Pharma File: Anumana has announced the FDA had granted breakthrough Device Designation to its AI-enhanced ECG-based Pulmonary Hypertension (PH) Early Detection Algorithm. Breakthrough Device Designations recognise novel innovations demonstrating potential…May 24, 2022
Anumana Collaborates with Leading Global Health Care Company to Detect Heart Disease Using Artificial Intelligence
AI Thority: Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has launched a multi-year strategic collaboration with Novartis Pharmaceuticals Corporation (“Novartis”) to deploy a series of…July 12, 2022


